Many studies have suggested that one of the major mechanisms of anti‐PD‐1 therapies is to revert the dysfunctional phenotypes of tumor‐infiltrating exhausted CD8+ T cells and enable them to better kill and control cancer cells.67 Here, CD8A is linked to neoplasm.